<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MIACALCIN- calcitonin salmon injection, solution </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use MIACALCIN injection safely and effectively. See full prescribing information for MIACALCIN injection.</span><br><br><span class="Bold">MIACALCIN<span class="Sup">® </span>(calcitonin-salmon) injection, synthetic, for subcutaneous or intramuscular use</span><br><span class="Bold">Initial U.S. Approval: 1975</span><br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (<a href="#s1p4">1.4</a>)
		     
	3/2014 </p>
<p class="Highlighta">Warnings and Precautions (<a href="#s5p3">5.3</a>)      
	3/2014 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: </p>
<ul class="Disc">
<li>Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable (<a href="#s1p1">1.1</a>)</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (<a href="#s1p2">1.2</a>)</li>
<li>Treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> when alternative treatments are not suitable. <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> reduction efficacy has not been demonstrated (<a href="#s1p3">1.3</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Limitations of Use:</span> </p>
<ul class="Disc"><li>Due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis (<a href="#s1p4">1.4</a>, <a href="#s5p3">5.3</a>)</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Symptomatic Paget’s disease of bone: 100 International Units daily. Ensure adequate calcium and vitamin D intake (<a href="#s2p1">2.1</a>, <a href="#s2p5">2.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>: start with 4 International Units/kg body weight every 12 hours. Increase to 8 International Units/kg every 12 hours if no improvement in 1-2 days. Increase further to 8 International Units/kg every 6 hours if no improvement after 2 more days (<a href="#s2p2">2.2</a>)</li>
<li>Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>: 100 International Units daily. Ensure adequate calcium and vitamin D intake (<a href="#s2p3">2.3</a>, <a href="#s2p5">2.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Injection: 200 International Units per mL sterile solution in 2 mL multi-dose vials (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to calcitonin-salmon or any of the excipients (<a href="#s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including reports of fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Consider skin testing prior to treatment in patients with suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to calcitonin-salmon (<a href="#s5p1">5.1</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> has been reported. Ensure adequate intake of calcium and vitamin D (<a href="#s5p2">5.2</a>)<br>
</li>
<li>Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin-salmon-treated patients (<a href="#s5p3">5.3</a>, <a href="#s6p1">6.1</a>)<br>
</li>
<li>Circulating antibodies to calcitonin-salmon may develop, and may cause loss of response to treatment (<a href="#s5p4">5.4</a>)
<br>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (10%), <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span> (10%), and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face or hands (2-5%) (<a href="#s6">6</a>) </p>
<p class="Highlighta"><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Concomitant use of calcitonin-salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment (<a href="#s7">7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>There are no data to support use in children (<a href="#s8p4">8.4</a>)<br>
</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1     INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1     Treatment of Paget’s Disease of Bone</a></h2>
<h2><a href="#section-1.2" class="toc">1.2     Treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3     Treatment of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4     Important Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2     DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1     Paget’s Disease of Bone</a></h2>
<h2><a href="#section-2.2" class="toc">2.2     <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3     Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4     Preparation and Administration</a></h2>
<h2><a href="#section-2.5" class="toc">2.5     Recommendations for Calcium and Vitamin D Supplementation</a></h2>
<h1><a href="#section-3" class="toc">3     DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4     CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5     WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3     Malignancy</a></h2>
<h2><a href="#section-5.4" class="toc">5.4     Antibody Formation</a></h2>
<h2><a href="#section-5.5" class="toc">5.5     Urine Sediment Abnormalities </a></h2>
<h1><a href="#section-6" class="toc">6     ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1     Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2     Postmarketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3     Immunogenicity</a></h2>
<h1><a href="#section-7" class="toc">7     DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8     USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1     Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3     Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4     Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5     Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10     OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11     DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12     CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1     Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2     Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3     Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13     NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14     CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc">14.1     Paget’s Disease of Bone</a></h2>
<h2><a href="#section-13.2" class="toc">14.2     <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3     Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h1><a href="#section-14" class="toc">16     HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17     PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1     INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p1"></a><a name="section-1.1"></a><p></p>
<h2>1.1     Treatment of Paget’s Disease of Bone</h2>
<p class="First">Miacalcin injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. There is no evidence that the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of calcitonin-salmon is beneficial in asymptomatic patients. Miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p2"></a><a name="section-1.2"></a><p></p>
<h2>1.2     Treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p3"></a><a name="section-1.3"></a><p></p>
<h2>1.3     Treatment of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">Miacalcin injection is indicated for the treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> in women greater than 5 years postmenopause. The evidence of efficacy for calcitonin-salmon injection is based on increases in total body calcium observed in clinical trials. <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> reduction efficacy has not been demonstrated. Miacalcin injection should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p4"></a><a name="section-1.4"></a><p></p>
<h2>1.4     Important Limitations of Use</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2     DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>2.1     Paget’s Disease of Bone</h2>
<p class="First">The recommended dose of Miacalcin injection for treatment of symptomatic Paget's disease of bone is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2>2.2     <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">The recommended starting dose of Miacalcin injection for early treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> is 4 International Units/kg body weight every 12 hours by subcutaneous or intramuscular injection. If the response to this dose is not satisfactory after one or two days, the dose may be increased to 8 International Units/kg every 12 hours. If the response remains unsatisfactory after two more days, the dose may be further increased to a maximum of 8 International Units/kg every 6 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2>2.3     Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">The recommended dose of Miacalcin injection for treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> in women greater than 5 years postmenopause is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly. The minimum effective dose of Miacalcin injection for the prevention of vertebral bone mineral density loss has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2>2.4     Preparation and Administration</h2>
<p class="First">Visually inspect Miacalcin vials. Miacalcin injection is a clear, colorless, solution. If the solution is not clear and colorless, or contains any particles, or if the vial is damaged, do not administer the solution.</p>
<p>If the volume of Miacalcin injection to be injected exceeds 2 mL, intramuscular injection is preferable and the total dose should be distributed across multiple sites of injection.</p>
<p>Instruct patients to use sterile injection technique when administering Miacalcin injection, and to dispose of needles properly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p5"></a><a name="section-2.5"></a><p></p>
<h2>2.5     Recommendations for Calcium and Vitamin D Supplementation</h2>
<p class="First">Patients who use Miacalcin injection for treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3     DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Miacalcin injection is available as a clear, colorless, sterile solution of synthetic calcitonin-salmon in individual 2 mL multi-dose vials containing 200 International Units per mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4     CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to calcitonin-salmon or any of the excipients. Reactions have included <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5     WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>5.1     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported in patients receiving Miacalcin injection, e.g., <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Appropriate medical support and monitoring measures should be readily available when Miacalcin injection is administered. If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur, initiate appropriate treatment <span class="Italics">[see Contraindications (4)]</span>.</p>
<p>For patients with suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to calcitonin-salmon, skin testing should be considered prior to treatment utilizing a dilute, sterile solution of Miacalcin injection. Healthcare providers may wish to refer patients who require skin testing to an allergist. A detailed skin testing protocol is available from the Medical Services Department of Novartis Pharmaceuticals Corporation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> associated with <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> (i.e., <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>) and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity has been reported with Miacalcin injection therapy. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> must be corrected before initiating therapy. Other disorders affecting mineral metabolism (such as <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span>) should also be effectively treated. In patients at risk for <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, provisions for parenteral calcium administration should be available during the first several administrations of calcitonin-salmon and serum calcium and symptoms of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> should be monitored. Use of Miacalcin injection for the treatment of Paget’s disease or postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> is recommended in conjunction with an adequate intake of calcium and vitamin D <span class="Italics">[see Dosage and Administration (2.5)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>5.3     Malignancy</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In a meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon (nasal spray or investigational oral formulations), the overall incidence of malignancies reported was higher among calcitonin-salmon-treated patients (4.1%) compared with placebo-treated patients (2.9%). This suggests an increased risk of malignancies in calcitonin-salmon-treated patients compared to placebo-treated patients. It is not possible to exclude an increased risk when calcitonin-salmon is administered long-term subcutaneously, intramuscularly, or intravenously. The benefits for the individual patient should be carefully considered against possible risks <span class="Italics">[see Adverse Reactions (6.1)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2>5.4     Antibody Formation</h2>
<p class="First">Circulating antibodies to calcitonin-salmon have been reported with Miacalcin injection. The possibility of antibody formation should be considered in any patient with an initial response to Miacalcin injection who later stops responding to treatment <span class="Italics">[see Adverse Reactions (6.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>5.5     Urine Sediment Abnormalities </h2>
<p class="First">Coarse granular casts and casts containing renal tubular epithelial cells were reported in young adult volunteers at bed rest who were given injectable calcitonin-salmon to study the effect of immobilization on <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. There was no other evidence of renal abnormality and the urine sediment normalized after calcitonin-salmon was stopped. Periodic examinations of urine sediment should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6     ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span><br>
</li>
<li>Malignancy <span class="Italics">[see Warnings and Precautions (5.3)]</span><br>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2>6.1     Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of calcitonin-salmon injection was assessed in open-label trials several months to two years in duration. The most common adverse reactions are discussed below.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has been noted in about 10% of patients treated with calcitonin-salmon. It is most evident when treatment is first initiated and tends to decrease or disappear with continued administration.</p>
<p><span class="Bold">Dermatologic Reactions</span>: Local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> at the site of subcutaneous or intramuscular injection have been reported in about 10% of patients. <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing of face</span> or hands occurred in about 2%-5% of patients. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> of the ear lobes have also been reported.</p>
<p><span class="Bold">Other Adverse Reactions</span>: <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span>, feverish sensation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the eyes, poor appetite, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4010362" conceptname="Edema of foot">pedal edema</span>, and salty taste have been reported in patients treated with calcitonin-salmon injection. </p>
<p><span class="Bold Underline">Malignancy</span></p>
<p>A meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon (nasal spray or investigational oral formulations) was conducted to assess the risk of malignancies in calcitonin-salmon-treated patients compared to placebo-treated patients. The trials in the meta-analysis ranged in duration from 6 months to 5 years and included a total of 10883 patients (6151 treated with calcitonin-salmon and 4732 treated with placebo). The overall incidence of malignancies reported in these 21 trials was higher among calcitonin-salmon-treated patients (254/6151 or 4.1%) compared with placebo-treated patients (137/4732 or 2.9%). Findings were similar when analyses were restricted to the 18 nasal spray only trials [calcitonin-salmon 122/2712 (4.5%); placebo 30/1309 (2.3%)].</p>
<p>The meta-analysis results suggest an increased risk of overall malignancies in calcitonin-salmon-treated patients compared to placebo-treated patients when all 21 trials are included and when the analysis is restricted to the 18 nasal spray only trials (see Table 1). It is not possible to exclude an increased risk when calcitonin-salmon is administered by the subcutaneous, intramuscular, or intravenous route because these routes of administration were not investigated in the meta-analysis. The increased malignancy risk seen with the meta-analysis was heavily influenced by a single large 5-year trial, which had an observed risk difference of 3.4% [95% CI (0.4%, 6.5%)]. Imbalances in risks were still observed when analyses excluded basal cell carcinoma (see Table 1); the data were not sufficient for further analyses by type of malignancy. A mechanism for these observations has not been identified. Although a definitive causal relationship between calcitonin-salmon use and malignancies cannot be established from this meta-analysis, the benefits for the individual patient should be carefully evaluated against all possible risks <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
<table>
<caption><span>Table 1: Risk Difference for Malignancies in Calcitonin-Salmon-Treated Patients Compared with Placebo-Treated Patients</span></caption>
<col width="200">
<col width="200">
<col width="200">
<col width="250">
<tfoot><tr class="First Last"><td class="Toprule" colspan="4">
<span class="Sup">1</span> The overall adjusted risk difference is the difference between the percentage of patients who had any malignancy (or malignancy excluding basal cell carcinoma) in calcitonin-salmon and placebo treatment groups, using the Mantel-Haenszel (MH) fixed-effect method. A risk difference of 0 is suggestive of no difference in malignancy risks between the treatment groups. <br><span class="Sup">2</span> The corresponding 95% confidence interval for the overall adjusted risk difference also based on MH fixed-effect method.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Patients</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Malignancies</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Risk Difference<span class="Sup">1</span><br>(%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">95% Confidence Interval<span class="Sup">2</span> (%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">All (nasal spray + oral)</td>
<td class="Lrule Rrule Toprule">All</td>
<td class="Lrule Rrule Toprule" align="center">1.0</td>
<td class="Lrule Rrule Toprule" align="center">(0.3, 1.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">All (nasal spray + oral)</td>
<td class="Lrule Rrule Toprule">Excluding basal cell carcinoma</td>
<td class="Lrule Rrule Toprule" align="center">0.5</td>
<td class="Lrule Rrule Toprule" align="center">(-0.1, 1.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">All (nasal spray only)</td>
<td class="Lrule Rrule Toprule">All</td>
<td class="Lrule Rrule Toprule" align="center">1.4</td>
<td class="Lrule Rrule Toprule" align="center">(0.3, 2.6)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">All (nasal spray only)</td>
<td class="Lrule Rrule Toprule">Excluding basal cell carcinoma</td>
<td class="Lrule Rrule Toprule" align="center">0.8</td>
<td class="Lrule Rrule Toprule" align="center">(-0.2, 1.8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>6.2     Postmarketing Experience</h2>
<p class="First">Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions have been reported during post-approval use of Miacalcin injection.</p>
<p><span class="Italics Underline">Allergic / <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported in patients receiving calcitonin-salmon injection, e.g., <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Italics Underline">Skin and subcutaneous tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></span>: <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> with <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> (i.e. <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>) and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity have been reported.</p>
<p><span class="Italics Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (facial, peripheral, and generalized)</p>
<p><span class="Italics Underline">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span></p>
<p><span class="Italics Underline">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p><span class="Italics Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Italics Underline">Urinary System</span>: <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p>
<p><span class="Italics Underline">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Italics Underline">Vision</span>: <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p3"></a><a name="section-6.3"></a><p></p>
<h2>6.3     Immunogenicity</h2>
<p class="First">Consistent with the potentially immunogenic properties of medicinal products containing peptides, administration of Miacalcin may trigger the development of anti-calcitonin antibodies. Circulating antibodies to calcitonin-salmon after 2-18 months of treatment have been reported in about one-half of the patients with Paget’s disease in whom antibody studies were done. In some cases, high antibody titers are found; these patients usually will have a loss of response to treatment <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p>The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of a positive antibody test result may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of antibodies among different calcitonin-salmon products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7     DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies have been performed with Miacalcin injection.</p>
<p>Concomitant use of calcitonin-salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8     USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8p1"></a><a name="section-8.1"></a><p></p>
<h2>8.1     Pregnancy</h2>
<p class="First">Pregnancy Category C:</p>
<p><span class="Underline">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Miacalcin injection should be used during pregnancy only if the potential benefit justifies the use as compared with potential risks to the patient and fetus. Based on animal data, Miacalcin is predicted to have low probability of increasing the risk of adverse developmental outcomes above background risk.</p>
<p><span class="Underline">Animal Data</span></p>
<p>Calcitonin-salmon has been shown to cause a decrease in fetal birth weights in rabbits when given by subcutaneous injection in doses 4-18 times the parenteral dose recommended for human use (of 54 International Units/m<span class="Sup">2</span>).</p>
<p>No embryo/fetal toxicities related to Miacalcin were reported from maternal subcutaneous daily doses in rats up to 80 International Units /kg/day from gestation day 6 to 15.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.2"></a><p></p>
<h2>8.3     Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. No studies have been conducted to assess the impact of Miacalcin on milk production in humans, its presence in human breast milk, or its effects on the breastfed child. Because many drugs are excreted in human milk, caution should be exercised when Miacalcin is administered to a nursing woman. Calcitonin has been shown to inhibit lactation in rats.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.3"></a><p></p>
<h2>8.4     Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.4"></a><p></p>
<h2>8.5     Geriatric Use</h2>
<p class="First">Clinical studies of Miacalcin injection did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10     OVERDOSAGE</h1>
<p class="First">The pharmacologic actions of Miacalcin injection suggest that <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">hypocalcemic tetany</span> could occur in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Therefore, provisions for parenteral administration of calcium should be available for the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>A dose of calcitonin-salmon l000 International Units subcutaneously may produce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Doses of 32 International Units per kg per day for 1-2 days demonstrate no other adverse effects. Data on chronic high-dose administration are insufficient to assess toxicity.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11     DESCRIPTION</h1>
<p class="First">Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish.</p>
<p>Miacalcin (calcitonin-salmon) injection, synthetic is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin. This is shown by the following graphic formula:</p>
<p><img alt="graphic formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f9d5a587-e2bc-4001-987d-9b04731303cb&amp;name=miacalcin-injectable-01.jpg"></p>
<p>It is provided in sterile solution for subcutaneous or intramuscular injection. Each milliliter contains: calcitonin-salmon 200 International Units.</p>
<p><span class="Italics">Inactive Ingredients (per mL)</span>: acetic acid, USP, 2.25 mg; phenol, USP, 5.0 mg; sodium acetate trihydrate, USP, 2.0 mg; sodium chloride, USP, 7.5 mg; water for injection, USP.</p>
<p>The activity of Miacalcin injection is stated in International Units based on bioassay in comparison with the International Reference Preparation of calcitonin-salmon for Bioassay, distributed by the National Institute for Biological Standards and Control, Holly Hill, London.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12     CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1     Mechanism of Action</h2>
<p class="First">Calcitonin-salmon is a calcitonin receptor agonist. Calcitonin-salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action.</p>
<p>The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2     Pharmacodynamics</h2>
<p class="First"><span class="Underline">Bone</span></p>
<p>Single injections of calcitonin-salmon caused a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity.</p>
<p>In healthy adults, who have a relatively low rate of bone resorption, the administration of exogenous calcitonin-salmon results in decreases in serum calcium within the limits of the normal range. In healthy children and in patients whose bone resorption is more rapid, decreases in serum calcium are more pronounced in response to calcitonin-salmon.</p>
<p><span class="Underline">Kidney</span></p>
<p>Studies with injectable calcitonin-salmon show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption.</p>
<p><span class="Underline">Gastrointestinal Tract</span></p>
<p>Some evidence from studies with injectable preparations suggests that calcitonin-salmon may have effects on the gastrointestinal tract. Short-term administration of injectable calcitonin-salmon results in marked transient decreases in the volume and acidity of gastric juice and in the volume and the trypsin and amylase content of pancreatic juice. Whether these effects continue to be elicited after each injection of calcitonin-salmon during chronic therapy has not been investigated.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3     Pharmacokinetics</h2>
<p class="First">The absolute bioavailability of calcitonin-salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively. After subcutaneous administration, peak plasma levels are reached in approximately 23 minutes. The terminal half-life is approximately 58 minutes for intramuscular administration and 59 to 64 minutes for subcutaneous administration. The apparent volume of distribution is 0.15-0.3 L/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13     NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Carcinogenicity</span></p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> was increased in rats after one and two years of subcutaneous exposure to synthetic calcitonin-salmon. The significance of this finding to humans is unknown because <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> are very common in rats as they age, the <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> did not transform into metastatic tumors, there were no other clear treatment- related neoplasms, and synthetic calcitonin-salmon related neoplasms were not observed in mice after two years of dosing.</p>
<p><span class="Italics">Rat findings:</span></p>
<p>The only clear neoplastic finding in rats dosed subcutaneously with calcitonin-salmon was an increase in the incidence of <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> in male Fisher 344 rats and female Sprague Dawley rats after one year of dosing and male Sprague Dawley rats dosed for one and two years. In female Sprague Dawley rats, the incidence of <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> after two years was high in all treatment groups (between 80% and 92% including the control groups) such that a treatment-related effect could not be distinguished from natural background incidence. The lowest dose in male Sprague Dawley rats that developed an increased incidence of <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> after two years of dosing (1.7 International Units/kg/day) is approximately 1/6<span class="Sup">th</span> of the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between rats and humans. The findings suggest that calcitonin-salmon reduced the latency period for development of non-functioning <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span>.</p>
<p><span class="Italics">Mouse findings:</span></p>
<p>No carcinogenicity potential was evident in male or female mice dosed subcutaneously for two years with synthetic calcitonin-salmon at doses up to 800 International Units/kg/day. The 800 International Units/kg/day dose is approximately 39 times the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between mice and humans.</p>
<p><span class="Bold">Mutagenesis</span></p>
<p>Synthetic calcitonin-salmon tested negative for mutagenicity using <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (5 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) and <span class="Italics">Escherichia coli</span> (2 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), with and without rat liver metabolic activation, and was not clastogenic in a chromosome aberration test in Chinese Hamster V79 cells. There was no evidence that calcitonin-salmon was clastogenic in the in vivo mouse micronucleus test.</p>
<p><span class="Bold">Fertility</span></p>
<p>Effects of calcitonin-salmon on fertility have not been assessed in animals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14     CLINICAL STUDIES</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1     Paget’s Disease of Bone</h2>
<p class="First">The trials used for the basis of approval for calcitonin-salmon injection for treatment of Paget’s disease of bone were conducted in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. In open-label clinical trials of several months to two years duration with historical controls, biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. There is too little experience to predict the likelihood of improvement of any given neurologic lesion. <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> is improved infrequently (4 of 29 patients studied by audiometry). Patients with increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> due to extensive Paget’s disease of bone have had measured decreases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> while receiving calcitonin-salmon. The number of treated patients in this category is too small to predict how likely such a result will be.</p>
<p>There is no evidence that the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of calcitonin-salmon is beneficial in asymptomatic patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2     <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">In four open-label clinical trials enrolling 53 patients, calcitonin-salmon has been shown to lower elevated serum calcium levels of patients with carcinoma (with or without <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>), <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, and <span class="product-label-link" type="condition" conceptid="136934" conceptname="Primary hyperparathyroidism">primary hyperparathyroidism</span> (lesser response). These patients were treated with calcitonin-salmon only when other methods of lowering serum calcium (hydration, oral phosphate, corticosteroids) were unsuccessful or unsuitable. With patients’ pre-therapy serum calcium levels as controls, reduction in serum calcium was evident within 1-2 hours of administration. The peak effect occurred within 24-48 hours of injection and administration of calcitonin-salmon every 12 hours maintained a hypocalcemic effect for approximately 5-8 days, the time period evaluated for most patients in the clinical trials. The average reduction of 8-hour post-injection serum calcium was approximately 9% (2-3 mg/dL). Patients with higher values of serum calcium tended to show greater reductions during calcitonin-salmon treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>14.3     Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">The trials used for the basis of approval for calcitonin-salmon injection for treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> were two randomized, open-label, 2-year studies in postmenopausal women 50–74 years of age with total body calcium &lt;85% of expected normal, and vertebral <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span> (by x-ray criteria) and/or at least one atraumatic <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fracture</span>. The primary efficacy endpoint was total body calcium measured by neutron activation analysis. Patients were randomized to calcitonin-salmon injection 100 International Units daily (subcutaneously or intramuscularly) at bedtime, or control. All subjects received daily supplements of 1200 mg calcium carbonate and 400 International Units of vitamin D.</p>
<p>In both studies, total body calcium increased from baseline with calcitonin-salmon therapy at 1 year, followed by a trend to decreasing total body calcium (still above baseline) at 2 years.</p>
<p>Thoracic and lumbar spine X-rays (AP/lateral) were obtained yearly. For the two studies combined (34 calcitonin-salmon and 35 control subjects), in the first year there was a total of 6 new vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span> in the calcitonin-salmon group and 5 in the control group. In the second year there were 7 new <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in each group.</p>
<p>No evidence currently exists to indicate whether Miacalcin injection decreases the risk of <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fracture</span>. A controlled study, which was prematurely discontinued, failed to demonstrate any benefit of calcitonin-salmon on <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> rate.</p>
<p>No adequate controlled trials have examined the effect of calcitonin-salmon injection on vertebral bone mineral density beyond 1 year of treatment. Therefore, the minimum effective dose of Miacalcin injection for prevention of vertebral bone mineral density loss has not been established.</p>
<p>In clinical studies of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, bone biopsy and radial bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> assessments at baseline and after 26 months of daily injectable calcitonin-salmon indicate that calcitonin therapy results in the formation of normal bone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16     HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">How Supplied</span></p>
<p>Miacalcin (calcitonin-salmon) injection, synthetic is available as a sterile solution in individual 2 mL multi-dose vials containing 200 International Units per mL .......................NDC 0078-0149-23</p>
<p><span class="Bold">Storage and Handling</span></p>
<p>Store in refrigerator between 2°C-8°C (36°F-46°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17     PATIENT COUNSELING INFORMATION</span></h1>
<ul>
<li>Instruct patients and other persons who may administer Miacalcin injection in sterile injection technique. Also instruct patients to dispose of needles properly <span class="Italics">[see Dosage and Administration (2.4)]</span>.</li>
<li>Inform patients of the potential increase in risk of malignancy <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</li>
<li>Advise patients with postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> or Paget’s disease of bone to maintain an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day) intake <span class="Italics">[see Dosage and Administration (2.5)]</span>.</li>
<li>Instruct patients to seek emergency medical help or go to the nearest hospital emergency room right away if they develop any signs or symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</li>
</ul>
<p class="First">Distributed by:<br>Novartis Pharmaceuticals Corporation<br>East Hanover, New Jersey 07936 </p>
<p>© Novartis</p>
<p>T2015-50<br>February 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">Package Label – </span><span class="Bold">2 mL</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0149-23</p>
<p>Miacalcin®</p>
<p>(calcitonin-salmon)</p>
<p>Injection, Synthetic</p>
<p>200 I.U. per mL.</p>
<p>400 I.U./2 mL Multi-dose vial</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label – 2 mL
Rx Only		NDC 0078-0149-23
Miacalcin® (calcitonin-salmon) Injection, Synthetic
200 I.U. per mL.
2 mL Multi-dose vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f9d5a587-e2bc-4001-987d-9b04731303cb&amp;name=miacalcin-injectable-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MIACALCIN 		
					</strong><br><span class="contentTableReg">calcitonin salmon injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0149</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCITONIN SALMON</strong> (CALCITONIN SALMON) </td>
<td class="formItem">CALCITONIN SALMON</td>
<td class="formItem">200.0 [iU]  in 1.0 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">2.25 mg  in 1.0 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">5.0 mg  in 1.0 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">2.0 mg  in 1.0 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7.5 mg  in 1.0 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0149-23</td>
<td class="formItem">2.0 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017808</td>
<td class="formItem">07/03/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Pharmaceuticals Corporation
							(002147023)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>223dc129-c720-41ba-a4e6-d879ea89431d</div>
<div>Set id: f9d5a587-e2bc-4001-987d-9b04731303cb</div>
<div>Version: 6</div>
<div>Effective Time: 20150202</div>
</div>
</div> <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
